Alec Barclay - T2 Biosystems Senior Vice President - Operations
| TTOODelisted Stock | USD 0.18 0.05 21.74% |
President
Mr. Alec Barclay is Senior Vice President Operations of the Company. He has served as our Senior Vice President, Operations since March 2018. Mr. Barclay joined our company in April 2016 as Vice President of Product Development and Product Management. Mr. Barclay joined our company in April 2016 as Vice President of Product Development and Program Management. Prior to joining the Company, Mr. Barclay served as the Director of Hardware and Systems Engineering at Becton Dickinson, a medical technology company that manufactures and sells medical devices, instrument systems, and reagents, within their Genomics division from January 2015 to April 2016. Prior to joining Becton Dickinson, he held various positions within Siemens Healthcare from July 2006 to December 2014, with his last assignment serving as Senior Manager, Lead Systems Integrator since 2018.
| Age | 44 |
| Tenure | 7 years |
| Phone | 781 761 4646 |
| Web | https://www.t2biosystems.com |
T2 Biosystems Management Efficiency
The company has return on total asset (ROA) of (0.9046) % which means that it has lost $0.9046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.2214) %, meaning that it created substantial loss on money invested by shareholders. T2 Biosystems' management efficiency ratios could be used to measure how well T2 Biosystems manages its routine affairs as well as how well it operates its assets and liabilities.T2 Biosystems currently holds 49.5 M in liabilities with Debt to Equity (D/E) ratio of 6.64, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. T2 Biosystems has a current ratio of 1.83, which is within standard range for the sector. Debt can assist T2 Biosystems until it has trouble settling it off, either with new capital or with free cash flow. So, T2 Biosystems' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like T2 Biosystems sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TTOO to invest in growth at high rates of return. When we think about T2 Biosystems' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Stephen Williamson | Thermo Fisher Scientific | 58 | |
| Mark Stevenson | Thermo Fisher Scientific | 57 | |
| Michael Lane | IDEXX Laboratories | 56 | |
| Robert Carson | Waters | 46 | |
| William King | Danaher | 53 | |
| Peter Hornstra | Thermo Fisher Scientific | 59 | |
| Daniel Comas | Danaher | 55 | |
| Sharon Underberg | IDEXX Laboratories | 63 | |
| Joakim Weidemanis | Danaher | 55 | |
| Matthew McGrew | Danaher | 53 | |
| Robert Lutz | Danaher | 62 | |
| Michael Harrington | Waters | 59 | |
| Michel Lagarde | Thermo Fisher Scientific | 50 | |
| Daniel Raskas | Danaher | 54 | |
| Elizabeth Rae | Waters | 60 | |
| John Lynch | Waters | N/A | |
| Ian King | Waters | 63 | |
| Katharyn Field | iSpecimen | 41 | |
| Sherry Buck | Waters | 55 | |
| Michael Boxer | Thermo Fisher Scientific | 58 | |
| Brian Ellis | Danaher | 57 | |
Management Performance
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 |
T2 Biosystems Leadership Team
Elected by the shareholders, the T2 Biosystems' board of directors comprises two types of representatives: T2 Biosystems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TTOO. The board's role is to monitor T2 Biosystems' management team and ensure that shareholders' interests are well served. T2 Biosystems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, T2 Biosystems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Smith, Senior Development | ||
| Aparna MD, Chief Board | ||
| Kelley Morgan, Chief Officer | ||
| BSc III, CEO President | ||
| Michael Esq, Sr Counsel | ||
| Brett Giffin, Chief Officer | ||
| Alec Barclay, Senior Vice President - Operations | ||
| John CPA, Chief Officer |
TTOO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is T2 Biosystems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 21.91 M | ||||
| Shares Outstanding | 21.04 M | ||||
| Shares Owned By Insiders | 10.17 % | ||||
| Shares Owned By Institutions | 73.51 % | ||||
| Number Of Shares Shorted | 826.91 K | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in TTOO Pink Sheet
If you are still planning to invest in T2 Biosystems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the T2 Biosystems' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |